NurExone Biologic team members Lior Shaltiel, PhD, Lyora Aharonov and Inbar Paz Benayoun, Adv. at the MIXiii Health-Tech.IL in Jerusalem. It has been a pleasure to hear recent developments and network in the Life Science & health tech community! Read More…
Calgary, Alberta–(Newsfile Corp. – November 8, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by
